Branched chain DNA assay (bDNA), cytomegalovirus (CMV) antigen assay, and cerebrospinal fluid (CSF) viral culture were studied for their utility in the diagnosis of CMV polyradiculopathy and for documenting in vivo antiviral effects. CMV was demonstrated in 15 of 16 patients by bDNA assay, 15 of 16 by CMV antigen assay, and 11 of 15 by CSF culture. When clinical criteria and results of the other two assays were used as reference standards, the sensitivity of bDNA was 94% and 100% and the specificity 95.2% and 100%; the CMV antigen assay sensitivity was 94% and 100% and specificity was 85.7% and 100%. Nine (90%) of 10 patients with polyradiculopathy and follow-up CSF culture showed a drop in CMV DNA after treatment; however, only 2 (20%) improved clinically. These results suggest that bDNA and antigen assays may be useful methods for the diagnosis of CMV polyradiculopathy, but treatment failures may not be due to inadequate antiviral activity.
Cytomegalovirus (CMV) infection is a frequent cause of
cerebrospinal fluid (CSF) for CMV by use of tissue culture systems has been the reference standard for diagnosis, but it morbidity and mortality among patients with human immunodeficiency virus (HIV) infection. It is the most common opporlacks adequate sensitivity. It is estimated that CSF culture for CMV is only 50% sensitive for the detection of CMV neurotunistic viral pathogen in patients with AIDS and was found in the central nervous system (CNS) of 33% of AIDS patients logic diseases when all other diagnoses are excluded and diagnosis is confirmed by autopsy [6] . In addition, 1 -4 weeks in one autopsy report [1] . Neurologic disease caused by CMV includes polyradiculopathy, encephalopathy, myelopathy, may be required for CMV to grow in culture, since the rapid centrifuged shell vial cultures may be negative. Although emmononeuritis multiplex, and multifocal neuropathy [2] . While these clinical syndromes are responsible for severe neurologic piric treatment may be initiated, current therapies for CMV have serious and frequent adverse effects. For these reasons, sequelae and death in patients with AIDS, it is often difficult to definitively diagnose these conditions and differentiate them assays that can rapidly detect CMV with a high level of sensifrom other infections of the CNS. HIV encephalopathy, lymphtivity and specificity are needed. omatous meningitis, tuberculous meningitis, toxoplasmosis, Recently, polymerase chain reaction (PCR), which detects cryptococcal meningitis, and ascending demyelinating neuropnucleic acid, has been shown to be both sensitive and specific athy are among other CNS conditions that may present in a in detecting CMV in CSF but has not been evaluated as a manner similar to neurologic infection with CMV. The prognodiagnostic test for CMV neurologic disease [7 -10] . Moreover, sis of CMV neurologic disease, particularly polyradiculopathy, PCR does not always provide quantitation of virus in CSF, is very frequently poor unless the syndrome is recognized and and thus a quantitative response to therapy cannot be readily therapy is started rapidly [3 -5] .
measured. CMV antigen in CSF has been detected in a small A major obstacle to early diagnosis has been the absence number of patients with polyradiculopathy Branched DNA amplification assay. CSF (1-1.5 mL) was presubmitted was insufficient (defined as õ1 mL) or if medical recpared for bDNA assay by ultracentrifuging (TL-100 centrifuge; ords were not retrievable for review.
Beckman Instruments, Palo Alto, CA) at 100,000 g for 1 h. The resulting pellet was resuspended in 40 mL of medium and stored at 035ЊC. To the ultracentrifuged pellet was added 50 mL of
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protein kinase-K. The mixture was incubated at 65ЊC for 30 min.
To each tube was added 50 mL of denaturation buffer containing label and capture extender probes. The mixture was incubated at Medical records were retrospectively reviewed and data were abstracted regarding HIV status and stage, prior CMV disease, and 65ЊC for 30 min. Following this incubation, 50 mL of neutralization buffer was added. In replicates of three, 40 mL of each tube was therapy. Presenting neurologic complaints and physical examination abnormalities that prompted CSF analysis and the course and added to microwells that contained covalently bound capture probes. The microwell plates were incubated overnight at 65ЊC. response following therapy were also noted. Laboratory data, imaging studies, and electromyelography or electroencephalography
The next day, 40 mL of amplifier probe was added to each well. The plates were incubated at 53ЊC for 30 min; 40 mL of alkaline results for each patient were recorded. Cases were then categorized into groups based on a set of preformulated clinical criteria. The phosphatase-labeled probe was then added to each well and the plates were incubated for 15 min at 37ЊC. The chromogen, dioxecategories were as follows: CMV polyradiculopathy, probable CMV encephalitis, other diagnosis (another pathogen was identitane, was added to each well, and plates were incubated at 37ЊC for 30 min. Enzyme activity was then determined by luminometer fied), or unknown diagnosis (where the cause of neurologic symptoms remained uncertain). The case definitions for the CMV clinimeasurement. A standard curve was run using known amounts of CMV DNA to quantify positive signal. A signal of ú1 luminocal diagnoses are provided below.
A neurologist reviewer blinded to bDNA and CMV antigen meter unit/mL was considered positive. CMV antigen assay. The CMV antigen assay was performed assay results independently categorized patients on the basis of data obtained from medical charts. The sensitivity and specificity by using the CMV-VUE immunoperoxidase kit (INCSTAR, Stillwater, MN). This assay detects the early structural protein (PP65) of the bDNA assay and CMV antigen assay were calculated in comparison to the clinical diagnosis of polyradiculopathy. Polyraof CMV in CSF leukocytes by use of immunocytochemical methods. One milliliter of CSF was centrifuged in a microfuge at 14,000 diculopathy was used because it is a diagnosis that is more clearly defined clinically, easier to document in medical records, has fewer g for 5 min to pellet cells. The cells were suspended in 40 mL of medium. Next, 15 mL of the cell suspension was spotted on slides, competing differential diagnoses than (e.g.) encephalopathy, and thus is subject to less misclassification error than is encephalopaair dried, and fixed in acetone. The fixed cells were then incubated with a murine monoclonal antibody directed against PP65, folthy. The test performance of CMV bDNA was also assessed by comparing it to an alternative reference standard: the concordant lowed by immunoperoxidase staining with peroxidase-labeled antimouse IgG. Positively stained cells were then visualized by light results of two other CMV assays, CMV culture of CSF and CMV antigen in CSF. This latter method has the advantage of using tests microscopy. Results were reported qualitatively as either positive or negative; quantitation of the number of positive cells was not that detect CMV by different mechanisms to compare to the test in question.
attempted.
/ 9d2f$$au37 06-25-97 08:16:26 jinfa UC: J Infect were positive for CMV antigen in CSF (sensitivity Å 94%).
* One test was indeterminate because too few cells were present in CSF to detect CMV antigen.
Of 21 patients in the ''other diagnosis'' category, 3 had a positive antigen test result (specificity Å 85.7%). Of 12 patients with positive results in both the bDNA and culture assays, 12 were positive for antigen (sensitivity Å 100%).
Culture. CSF (0.5-1 mL) was inoculated into human diploid CMV culture. Compared to the diagnosis of polyradiculofibroblast cultures and examined daily for cytopathogenic effect. Suspected isolates were confirmed by immunofluorescence by uspathy and to the other two assays, the sensitivity of culture ing a monoclonal antibody to CMV antigen. was 73.3% and the specificity was 100%.
The bDNA assay, CMV antigen assay, and CMV culture were performed on each specimen if the volume of CSF was sufficient.
Response to Therapy One milliliter of CSF was required for bDNA assay, 0.5 mL for CMV antigen assay, and 0.5 mL for CMV culture. In some cases, Repeat lumbar puncture and CSF analyses following the only bDNA and CMV antigen tests were performed. initiation of therapy were performed within 3 weeks for 10 patients to assess response to therapy. Results of CMV antigen, bDNA, culture, cell count, glucose, and protein analyses of Results CSF prior to and following treatment are shown in table 2. All CSF was submitted for 58 patients from 6 hospitals from 1 patients had been treated with ganciclovir, foscarnet, or both June 1993 through 30 July 1994. Forty-nine patients had medifor their neurologic syndromes. The median time of follow-up cal charts available for review and sufficient quantity of CSF was 13 days (range, 6 -17). for testing. All but 1 patient had documented AIDS. Of those
The bDNA signal declined in 9 patients after a mean of 11.5 diagnosed with CMV polyradiculopathy with documented CD4 days of treatment and in as few as 6 days. The bDNA signal cell counts (14/16), all had CD4 cell counts below 70 cells/ failed to decrease in 1 patient (patient 10) after 13 days of mm 3 (range, 0 -67; median, 15). treatment. In contrast, the CMV antigen assay remained posiThe neurologic presentations of patients are as follows: 16 tive in 5 of 10 treated patients, although quantitative evaluation patients presented with polyradiculopathy, 2 with probable of the number of positive cells was not performed. Culture CMV encephalopathy, 10 with neurologic symptoms of unremained positive in 2 of 6 patients with repeat study. known etiology, and 21 with other diagnoses. These other diagnoses included cryptococcal meningitis; CNS lymphoma; proDiscussion gressive multifocal leukoencephalopathy; normal pressure hydrocephalus; headache or altered mental status that was eiThese data demonstrate the utility of CMV bDNA assay and ther very transient, responsive rapidly to non-CMV therapy, or the CMV antigen assay for the detection of CMV neurologic longstanding dementia; HIV sensory peripheral neuropathy; infections, specifically CMV polyradiculopathy. Of 49 patients, and chronic inflammatory demyelinating polyneuropathy.
16 had syndromes compatible with polyradiculopathy; 15 of these 16 had positive bDNA assays and CMV antigen in CSF but only 11 of 15 had a positive culture. Several recent studies have indicated excellent sensitivity that factors other than antiviral susceptibility are important determinants of the outcome of polyradiculopathy. Among the results with PCR for detection of CMV in CSF, but they have not assessed the sensitivity for diagnosing a specific CMV most important of these may be early induction of therapy before an irreversible course is underway. Other studies suggest neurologic syndrome (e.g., polyradiculopathy), nor have they simultaneously compared results with those of at least two that a significant response to therapy in some patients may be achieved only after a substantial period of follow-up [13] . Our other assays [7 -10] . Prior to this study, detection of CMV antigen in CSF was evaluated only in patients with polyradicuresults underscore the need for rapid diagnosis, which may be achieved by using the bDNA or antigen assay. lopathy; however, it appeared useful in that study [11] .
PCR is not usually quantitative, and therefore, response to Several limitations of this study must be considered in the interpretation of these results: The retrospective nature of this therapy cannot be precisely measured and monitored over time. Our results show that CMV bDNA signal may decline in as investigation and relatively small number of CSF samples studied preclude definitive conclusions regarding test accuracy. few as 6 days after initiating therapy, thereby providing a rapid in vivo assay for antiviral susceptibility. Persistence of an eleHowever, this study does provide sufficient evidence that the assays under study may be useful as diagnostic tools and fill a vated bDNA signal despite therapy may indicate the presence of resistant virus. In this study, CMV antigen assay was not critical need, suggesting that further investigation is warranted. There is as yet no commercially available PCR assay for quantitated by counting the number of positive cells in serially collected samples. It is possible that the number of positive CMV, and we did not perform a head-to-head comparison with PCR technology. We therefore cannot determine the relative cells might have declined with treatment of susceptible CMV strains. Alternatively, quantitating the decline of antigen-posisensitivity and specificity of PCR in comparison to bDNA or CMV antigen assay. Such a study, with a prospective design, tive cells in response to antiviral therapy may have lagged behind the decline of viral DNA, since the available antivirals would permit further evaluation of these tests as diagnostic tools for CMV neurologic disease syndromes. inhibit viral DNA synthesis as their primary mode of action.
The bDNA assay also provides evidence that monotherapy One patient with a clinical diagnosis of chronic inflammatory demyelinating polyneuropathy had positive bDNA and CMV with ganciclovir or foscarnet, as well as the combination, does achieve adequate antiviral effect in CSF; therefore, this assay antigen results. In this patient, dual disease and misdiagnosis must be considered but are difficult to prove, since culture was could be used to determine the appropriate treatment for individual patients.
negative and clinical criteria for polyradiculopathy or probable / 9d2f$$au37 06-25-97 08:16:26 jinfa UC: J Infect
